$DCPH on NASDAQ
January 08, 2024
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
January 05, 2024
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
January 02, 2024
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
November 29, 2023
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 07, 2023
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
October 30, 2023
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
October 30, 2023
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
September 29, 2023
Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment
September 15, 2023
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2023
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2023
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
August 03, 2023
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
August 02, 2023
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
May 25, 2023
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
May 23, 2023
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
May 08, 2023
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
May 03, 2023
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
April 26, 2023
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
April 19, 2023
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
March 14, 2023
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
March 14, 2023
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 01, 2023
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
February 27, 2023
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
February 07, 2023
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
January 31, 2023
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
January 24, 2023
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 24, 2023
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
January 19, 2023
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 18, 2023
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 03, 2023
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
January 03, 2023
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
January 03, 2023
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 01, 2022
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
November 08, 2022
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
November 03, 2022
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
October 27, 2022
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
September 11, 2022
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
September 10, 2022
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022
September 01, 2022
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
August 19, 2022
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2022
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
August 04, 2022
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
July 28, 2022
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022
July 15, 2022
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
April 29, 2022
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
April 27, 2022
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
April 26, 2022
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
April 12, 2022
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
- No Recent Filings Found.
